THE RUSSIAN PHARMACEUTICAL MARKET: THE POSITION OF RUSSIAN COMPANIES

Introduction. The main efforts of Russian companies in 2011-2016 were aimed at implementing the import substitution strategy and at developing the domestic market. 44 import substitution drugs and 2 innovative ones were brought to the market in the framework of the implemented state program. The conducted industrial policy contributed to high investment activities in the industry. In 2011 to 2016, more than 120 billion rubles were invested into the pharmaceutical industry; more than 30 new production sites, including 7 plants, with foreign capital participation, were opened. Objective: to assess the positions of Russian companies on the domestic market and the benchmarks in the long-term development of Russian manufacture. Material and methods. The analysis was carried out on the basis of QuintilesIMS data, by using marketing and economic analysis methods. Results. Investigation of the sales of products made by Russian pharmaceutical manufacturers on the domestic market in 2015-2016 revealed a rise in the market share of domestic products in both the recoverable and commercial segments. The total market share in value terms reached 30%. Common trends are identified; factors contributing to positive changes are identified; the key role of them is played by the implemented government policy. Conclusion. In addition to import substitution, the long-term development of the Russian pharmaceutical industry is associated with the development of export activities, the necessary conditions for intensification of which are presently forming